Alvelestat (MPH996) for the Treatment of Alpha-1 Antitrypsin Deficiency (ATLANTa)

Phase: 2

Status: Ongoing

Details

Alvelestat (MPH996) for the Treatment of Alpha-1 Antitrypsin Deficiency (ATLANTa) – A Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of Alvelestat (MPH996) in alpha-1 antitrypsin deficiency

Sponsor: Mereo

IRB#: 1090

Sponsors

HOPE Cancer Center

Hope Cancer Center

Contact

Contact UT Clinical
Scroll to Top